	se through 12/31/2008. OMB 0851-00: e; U.S. DEPARTMENT OF COMMERC
TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A PENDING "REFERENCE" APPLICATION	2815-0445PUS1
In re Application of: Thomas J. JENTSCH	
Application No.: 10/622,377-Conf. #9926	
Filed: July 18, 2003	
For: TEST SYSTEM FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS, IN PARTICULAR ACTIVE COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS	
The owner*, Thomas J. JENTSCH	, of100
percent interest in the instant application hereby disclaims, except as provided below, the terminel part of the statutory term of any patent granted on the instant application which would extend beyond the expriging other of the full statutory term of any patent granted on pending reference Application Number 10/623, 150 filed on 10 July 18, 2003 as such larm is defined in 35 U.S.C. 154 and 173, and as the lem of lary patent granted on said reference application may be shortened by any terminal disclaimen filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent or granted on the instant application shall be enforceable only for and cuting such pend of that it and any patent granted on the reference application and to binding upon the granted, its successors or assigns.	
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the explosition dear of the full stallutory term as defined in \$5 U.S.C. 154 and 173 of any patent granted on asid reference application, "as the term of any patent granted on said reference application," any be shortened by any terminal disclaimer field prior to the grant of any patent on the pending reference application," in the event that any such patent; granted on the pending reference application: expires application: expires application: expires of the pending reference application; and the event that any such patent; granted on the pending reference application: expires for failure to pay a maintenance lete, is held unenforceable, is found invalid by a count of competerly undection, a stallutorily disclaimed in whose or terminately disclaimed under 3 CFR 1.321, has all claims as shortened by any terminal disclaiment comments of the expiration of fits full statutory term as shortened by any terminal disclaiment comments.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and beside are believed to be true; and turner that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Socion 1001 of Title 18 of the United States Octed and that such willful false statements may be generative the validity of the application or any patient issuand theeron.	
2. X The undersigned is an attorney or agent of regord. Reg. No. 40,069	
(Murphy & Reg No. 28977)	DEC 1 9 2008
Signyture	Date
Da√ MaryAnne Armstrong, Ph.D.	
Typed or printed name	
	(703) 205-8000
	Telephone Number
X Terminal disclaimer fee under 37 CFR 1,20(d) is included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card informationand authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	